The expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in patients with colorectal adenocarcinoma and lymph node metastases

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter F. Lumachi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors F. Lumachi1, F. Marino2, G. Chiara3, S. Basso3
  • 1Department of Surgery, Oncology & Gastroenterology, University of Padua, School of Medicine, Padova, Italy, /
  • 2Department of Pathology, University of Padua, School of Medicine, Padova, Italy, /
  • 3Chirurgia 1, S. Maria degli Angeli Hospital, Pordenone, Italy, /


In patients with colorectal cancer (CRC), the presence of lymph node (LN) metastases involvement seriously reduces recovery rate and survival. Unfortunately, despite a careful lymphadenectomy and subsequent histopathological assessment of resected LNs, up to 15-20% of N0 patients who underwent curative (R0) resection develop tumor recurrence. With the aim of reducing false-negative results, various more sensitive methods for tumor cell detection based on immunohistochemical techniques or reverse transcriptase polymerase chain reaction (RT-PCR) detection of mRNA, have been suggested. However, the aggressiveness of CRC and the subsequent likelihood of LNs or distant metastases mainly depends on proliferative activity of cancer cells within cancer tissue revealed by several measurable molecular markers, including proliferating cell nuclear antigen (PCNA) (a non-histamine nuclear protein), p53, COX-2, EGFR, HER2, and Ki-67 (a marker of mitotic activity) expression. The aim of this study was to evaluate the predictive value of Ki-67 overexpression and PCNA positivity in predicting the presence of LN metastases in patients with CRC.